Big pharmaceutical companies like Gilead Sciences, Novartis, Johnson & Johnson, and Bristol Myers Squibb are focusing on reducing the manufacturing turnaround time for personalised blood cancer treatments known as CAR-T therapies. These treatments involve re-engineering a patient’s T cells to attack malignant cells and are used for patients with aggressive advanced cancers. Currently priced between $400,000 and $600,000, these treatments…